Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Trial ID or NCT#

NCT00336765

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to adults with advanced solid tumors.

Official Title

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Branimir I Sikic

Contact us to find out if this trial is right for you.

Contact

Joanne Fehling
6507361694

View on ClinicalTrials.gov